Title: Full Text of HB2371
Official Title: 
Number of Sections: 1
Source: versions - Senate Amendment 002
Media Type: text/html

================================================================================

Section 1:
Full Text of HB2371 ILGA.GOV HB2371 - 104th General Assembly Sen. David KoehlerFiled: 5/28/2025   10400HB2371sam002LRB104 06098 BAB 26897 a1AMENDMENT TO HOUSE BILL 23712    AMENDMENT NO. ______. Amend House Bill 2371, AS AMENDED, 3by replacing everything after the enacting clause with the 4following: 5    "Section 1. Short title. This Act may be cited as the 6Patient Access to Pharmacy Protection Act. 7    Section 5. Findings. The General Assembly finds that:8    (1) It is within the traditional authority of the State to 9regulate the acquisition and delivery of drugs to pharmacies 10and providers.11    (2) The federal 340B statute is silent on distribution of 12340B-acquired drugs to 340B covered entities and their 13contract pharmacy partners.14    (3) The State's compelling interest in preserving and 15improving access to health care services requires it to ensure 16that 340B covered entities continue to be allowed to contract   10400HB2371sam002- 2 -LRB104 06098 BAB 26897 a1with pharmacies to receive 340B drugs and dispense them to the 2patients of 340B covered entities in accordance with federal 3law.4    (4) Addressing accessibility of these life-saving 5medications is a matter of health, safety, and welfare for the 6people of the State of Illinois. 7    Section 10. Definitions. As used in this Act:8    "340B contract pharmacy" means any pharmacy that is under 9contract with a 340B covered entity to dispense 340B drugs on 10behalf of the 340B covered entity and is either (i) located in 11Illinois and qualifies as a pharmacy under Section 3 of the 12Pharmacy Practice Act; or (ii) is located in a state, 13commonwealth, or territory of the United States, other than 14Illinois, and dispenses 340B drugs on behalf of the 340B 15covered entity.16    "340B covered entity" means an entity in Illinois that 17qualifies as a covered entity under Section 340B of the 18federal Public Health Service Act, 42 U.S.C. 256b(a)(4).19    "340B drug" means a drug that has been subject to any offer 20for reduced prices by a manufacturer pursuant to 42 U.S.C. 21256b and is purchased by a 340B covered entity. 22    "340B drug discount program" means the program established 23under Section 340B of the federal Public Health Service Act, 2442 U.S.C. 256b.25    "340B grantee" means an entity in Illinois that qualifies   10400HB2371sam002- 3 -LRB104 06098 BAB 26897 a1as a covered entity under subparagraphs (A)–(K) of paragraph 2(4) of subsection (a) of Section 340B of the federal Public 3Health Service Act, 42 U.S.C. 256b(a)(4)(A)-(K).4    "Critical Access Hospital" has the meaning given to that 5term in paragraph (4) of subsection (b) of Section 5-5e of the 6Illinois Public Aid Code.7    "Hospital" means a hospital licensed under the Hospital 8Licensing Act or University of Illinois Hospital Act.9    "Manufacturer" or "Pharmaceutical Manufacturer" has the 10meaning given to the term "manufacturer" in the Wholesale Drug 11Distribution Licensing Act. 12    "Person" includes a natural person, partnership, 13association, corporation, or any other legal business entity. 14"Person" does not include any federal or State government 15entity or body.16    "Safety-Net Hospital" has the meaning given to that term 17in Section 5-5e.1 of the Illinois Public Aid Code. 18    Section 15. Protection of patient access to pharmacy.19    (a) No person, including a pharmaceutical manufacturer, 20may deny, restrict, prohibit, condition, or otherwise 21interfere with, either directly or indirectly, the acquisition 22of a 340B drug by, or delivery of a 340B drug to, a 340B 23covered entity or a 340B contract pharmacy authorized to 24receive 340B drugs on behalf of the 340B covered entity unless 25the receipt is prohibited by federal law.  10400HB2371sam002- 4 -LRB104 06098 BAB 26897 a1    (b) No person, including a pharmaceutical manufacturer, 2may impose any restriction on the ability of a 340B covered 3entity to contract with or designate a 340B contract pharmacy, 4including restrictions relating to the number, location, 5ownership, or type of 340B contract pharmacy.6    (c) No person, including a pharmaceutical manufacturer, 7may require or compel a 340B covered entity or 340B contract 8pharmacy to:9        (1) submit or otherwise provide ingredient cost or 10    pricing data pertinent to 340B drugs unless required by 11    State or federal law;12        (2) institute requirements in any way relating to how 13    a 340B covered entity manages its inventory of 340B drugs 14    that are not required by a State or federal agency, 15    including requirements relating to the frequency or scope 16    of audits of inventory management systems of a 340B 17    covered entity or a 340B contract pharmacy; or18        (3) submit data or information that is not required by 19    a State or federal law as a condition for a 340B covered 20    entity, its 340B contract pharmacy, or a location 21    otherwise authorized by a 340B covered entity to receive 22    340B drugs.23    (d) Each individual transaction, as defined in 21 U.S.C. 24360eee-24, of 340B drugs that is subject to a prohibited act in 25subsections (a) and (b) shall constitute a separate violation 26of this Act.   10400HB2371sam002- 5 -LRB104 06098 BAB 26897 a1    Section 20. Reporting. On or before August 1, 2026 and 2each August 1 thereafter, a 340B covered entity shall submit a 3report to the General Assembly pursuant to this Section. For 4the purposes of this Section, the following covered entities 5are exempt until January 1, 2029 and will report on or before 6August 1, 2029 and each August 1 thereafter: hospitals with 7fewer than 100 licensed beds, Critical Access Hospitals, 8Safety-Net Hospitals, and 340B grantees. The report must 9include all of the following for the 340B covered entity's 10340B program:11        (1) the name of the 340B covered entity submitting the 12    report;13        (2) a copy of the 340B covered entity's annual 340B 14    program recertification;15        (3) whether a community benefits plan report is 16    required under Section 20 of the Community Benefits Act 17    and, if so, a copy of the 340B covered entity's community 18    benefits plan report, including a description of the 19    amount of charity care provided by the 340B covered 20    entity;21        (4) the aggregate acquisition cost for prescription 22    drugs obtained under the 340B program and dispensed or 23    administered to patients;24        (5) the aggregate payment amount received for all 25    drugs obtained under the 340B program and dispensed or   10400HB2371sam002- 6 -LRB104 06098 BAB 26897 a1    administered to patients;2        (6) the number of claims for prescription drugs 3    received under the 340B program;4        (7) the percentage of the 340B covered entity's claims 5    that were for prescription drugs obtained under the 340B 6    program;7        (8) a description of any adverse 340B program audits 8    within the preceding 12 months; and9        (9) a description of the impact of the 340B program on 10    the patients and the community served by the 340B covered 11    entity. 12    Section 25. Medicaid study.13    (a) By January 1, 2028, the Department of Healthcare and 14Family Services shall report to the General Assembly on the 15following for the total aggregated covered outpatient drug 16units dispensed or administered in this State for the prior 17calendar year in connection with the medical assistance 18program under the Illinois Public Aid Code, categorized by (i) 19fee-for-service and (ii) each managed care plan: 20        (1) the number of dispensed or administered covered 21    outpatient drug units; 22        (2) the number of dispensed or administered covered 23    outpatient drug units that were subject to a rebate under 24    42 U.S.C. 1396r-8; and25        (3) a reasonable estimate of net costs or savings to   10400HB2371sam002- 7 -LRB104 06098 BAB 26897 a1    the State's medical assistance program due to 340B covered 2    entity purchases of covered outpatient drug units at 340B 3    pricing. 4    (b) To the extent the Department of Healthcare and Family 5Services lacks information to provide a data element required 6under subsection (a), it shall provide a reasonable estimate 7based on all available information and an explanation of the 8information that it lacks. 9    Section 30. 340B prescription drug applicability. Each 10340B covered entity shall dispense or administer 340B drugs 11only when in connection with an outpatient health care service 12received by the patient within the last 18 months. 13    Section 35. Preventing duplication of 340B discounts. Each 14340B covered entity shall develop and maintain a policy that 15ensures it is not placing an order for a 340B drug to replenish 16a prior pharmacy dispense if any other 340B covered entity 17will place an order for a 340B drug to replenish the same prior 18pharmacy dispense. The policy shall also include a process to 19reimburse a manufacturer for any duplicate 340B discount the 20covered entity receives. The policy shall be filed annually 21with the General Assembly. 22    Section 40. Enforcement.23    (a) The Attorney General is authorized to enforce this Act   10400HB2371sam002- 8 -LRB104 06098 BAB 26897 a1under its general authority under the Attorney General Act.2    (b) Upon finding a violation of Section 15 of this Act, a 3court may order:4        (1) temporary, preliminary, or permanent injunctive 5    relief for any act, policy, or practice that violates this 6    Act;7        (2) money damages to be paid to the 340B covered 8    entity as a result of the violation of this Act;9        (3) the assessment of a civil penalty of up to $1,000 10    for each violation of Section 15; or11        (4) any other relief. 12    Section 45. Preemption. 13    (a) Nothing in this Act shall be construed or applied to be 14less restrictive than federal law for a person regulated by 15this Act.16    (b) Nothing in this Act shall be construed or applied in a 17manner that would conflict with:18        (1) applicable federal law; or19        (2) other laws of this State if the State law is 20    compatible with applicable federal law.21    (c) Limited distribution of a drug required under 21 22U.S.C. 355-1 may not to be construed as a violation of this 23Act. 24    Section 97. Severability. If any provision of this Act or   10400HB2371sam002- 9 -LRB104 06098 BAB 26897 a1its application to any person or circumstance is held invalid, 2the invalidity of that provision or application does not 3affect other provisions or applications of this Act that can 4be given effect without the invalid provision or application. 5Each paragraph defining "340B contract pharmacy" in Section 10 6is severable. 7    Section 99. Effective date. This Act takes effect upon 8becoming law.".


================================================================================

Raw Text:
Full Text of HB2371 ILGA.GOV HB2371 - 104th General Assembly Sen. David KoehlerFiled: 5/28/2025   10400HB2371sam002LRB104 06098 BAB 26897 a1AMENDMENT TO HOUSE BILL 23712    AMENDMENT NO. ______. Amend House Bill 2371, AS AMENDED, 3by replacing everything after the enacting clause with the 4following: 5    "Section 1. Short title. This Act may be cited as the 6Patient Access to Pharmacy Protection Act. 7    Section 5. Findings. The General Assembly finds that:8    (1) It is within the traditional authority of the State to 9regulate the acquisition and delivery of drugs to pharmacies 10and providers.11    (2) The federal 340B statute is silent on distribution of 12340B-acquired drugs to 340B covered entities and their 13contract pharmacy partners.14    (3) The State's compelling interest in preserving and 15improving access to health care services requires it to ensure 16that 340B covered entities continue to be allowed to contract   10400HB2371sam002- 2 -LRB104 06098 BAB 26897 a1with pharmacies to receive 340B drugs and dispense them to the 2patients of 340B covered entities in accordance with federal 3law.4    (4) Addressing accessibility of these life-saving 5medications is a matter of health, safety, and welfare for the 6people of the State of Illinois. 7    Section 10. Definitions. As used in this Act:8    "340B contract pharmacy" means any pharmacy that is under 9contract with a 340B covered entity to dispense 340B drugs on 10behalf of the 340B covered entity and is either (i) located in 11Illinois and qualifies as a pharmacy under Section 3 of the 12Pharmacy Practice Act; or (ii) is located in a state, 13commonwealth, or territory of the United States, other than 14Illinois, and dispenses 340B drugs on behalf of the 340B 15covered entity.16    "340B covered entity" means an entity in Illinois that 17qualifies as a covered entity under Section 340B of the 18federal Public Health Service Act, 42 U.S.C. 256b(a)(4).19    "340B drug" means a drug that has been subject to any offer 20for reduced prices by a manufacturer pursuant to 42 U.S.C. 21256b and is purchased by a 340B covered entity. 22    "340B drug discount program" means the program established 23under Section 340B of the federal Public Health Service Act, 2442 U.S.C. 256b.25    "340B grantee" means an entity in Illinois that qualifies   10400HB2371sam002- 3 -LRB104 06098 BAB 26897 a1as a covered entity under subparagraphs (A)–(K) of paragraph 2(4) of subsection (a) of Section 340B of the federal Public 3Health Service Act, 42 U.S.C. 256b(a)(4)(A)-(K).4    "Critical Access Hospital" has the meaning given to that 5term in paragraph (4) of subsection (b) of Section 5-5e of the 6Illinois Public Aid Code.7    "Hospital" means a hospital licensed under the Hospital 8Licensing Act or University of Illinois Hospital Act.9    "Manufacturer" or "Pharmaceutical Manufacturer" has the 10meaning given to the term "manufacturer" in the Wholesale Drug 11Distribution Licensing Act. 12    "Person" includes a natural person, partnership, 13association, corporation, or any other legal business entity. 14"Person" does not include any federal or State government 15entity or body.16    "Safety-Net Hospital" has the meaning given to that term 17in Section 5-5e.1 of the Illinois Public Aid Code. 18    Section 15. Protection of patient access to pharmacy.19    (a) No person, including a pharmaceutical manufacturer, 20may deny, restrict, prohibit, condition, or otherwise 21interfere with, either directly or indirectly, the acquisition 22of a 340B drug by, or delivery of a 340B drug to, a 340B 23covered entity or a 340B contract pharmacy authorized to 24receive 340B drugs on behalf of the 340B covered entity unless 25the receipt is prohibited by federal law.  10400HB2371sam002- 4 -LRB104 06098 BAB 26897 a1    (b) No person, including a pharmaceutical manufacturer, 2may impose any restriction on the ability of a 340B covered 3entity to contract with or designate a 340B contract pharmacy, 4including restrictions relating to the number, location, 5ownership, or type of 340B contract pharmacy.6    (c) No person, including a pharmaceutical manufacturer, 7may require or compel a 340B covered entity or 340B contract 8pharmacy to:9        (1) submit or otherwise provide ingredient cost or 10    pricing data pertinent to 340B drugs unless required by 11    State or federal law;12        (2) institute requirements in any way relating to how 13    a 340B covered entity manages its inventory of 340B drugs 14    that are not required by a State or federal agency, 15    including requirements relating to the frequency or scope 16    of audits of inventory management systems of a 340B 17    covered entity or a 340B contract pharmacy; or18        (3) submit data or information that is not required by 19    a State or federal law as a condition for a 340B covered 20    entity, its 340B contract pharmacy, or a location 21    otherwise authorized by a 340B covered entity to receive 22    340B drugs.23    (d) Each individual transaction, as defined in 21 U.S.C. 24360eee-24, of 340B drugs that is subject to a prohibited act in 25subsections (a) and (b) shall constitute a separate violation 26of this Act.   10400HB2371sam002- 5 -LRB104 06098 BAB 26897 a1    Section 20. Reporting. On or before August 1, 2026 and 2each August 1 thereafter, a 340B covered entity shall submit a 3report to the General Assembly pursuant to this Section. For 4the purposes of this Section, the following covered entities 5are exempt until January 1, 2029 and will report on or before 6August 1, 2029 and each August 1 thereafter: hospitals with 7fewer than 100 licensed beds, Critical Access Hospitals, 8Safety-Net Hospitals, and 340B grantees. The report must 9include all of the following for the 340B covered entity's 10340B program:11        (1) the name of the 340B covered entity submitting the 12    report;13        (2) a copy of the 340B covered entity's annual 340B 14    program recertification;15        (3) whether a community benefits plan report is 16    required under Section 20 of the Community Benefits Act 17    and, if so, a copy of the 340B covered entity's community 18    benefits plan report, including a description of the 19    amount of charity care provided by the 340B covered 20    entity;21        (4) the aggregate acquisition cost for prescription 22    drugs obtained under the 340B program and dispensed or 23    administered to patients;24        (5) the aggregate payment amount received for all 25    drugs obtained under the 340B program and dispensed or   10400HB2371sam002- 6 -LRB104 06098 BAB 26897 a1    administered to patients;2        (6) the number of claims for prescription drugs 3    received under the 340B program;4        (7) the percentage of the 340B covered entity's claims 5    that were for prescription drugs obtained under the 340B 6    program;7        (8) a description of any adverse 340B program audits 8    within the preceding 12 months; and9        (9) a description of the impact of the 340B program on 10    the patients and the community served by the 340B covered 11    entity. 12    Section 25. Medicaid study.13    (a) By January 1, 2028, the Department of Healthcare and 14Family Services shall report to the General Assembly on the 15following for the total aggregated covered outpatient drug 16units dispensed or administered in this State for the prior 17calendar year in connection with the medical assistance 18program under the Illinois Public Aid Code, categorized by (i) 19fee-for-service and (ii) each managed care plan: 20        (1) the number of dispensed or administered covered 21    outpatient drug units; 22        (2) the number of dispensed or administered covered 23    outpatient drug units that were subject to a rebate under 24    42 U.S.C. 1396r-8; and25        (3) a reasonable estimate of net costs or savings to   10400HB2371sam002- 7 -LRB104 06098 BAB 26897 a1    the State's medical assistance program due to 340B covered 2    entity purchases of covered outpatient drug units at 340B 3    pricing. 4    (b) To the extent the Department of Healthcare and Family 5Services lacks information to provide a data element required 6under subsection (a), it shall provide a reasonable estimate 7based on all available information and an explanation of the 8information that it lacks. 9    Section 30. 340B prescription drug applicability. Each 10340B covered entity shall dispense or administer 340B drugs 11only when in connection with an outpatient health care service 12received by the patient within the last 18 months. 13    Section 35. Preventing duplication of 340B discounts. Each 14340B covered entity shall develop and maintain a policy that 15ensures it is not placing an order for a 340B drug to replenish 16a prior pharmacy dispense if any other 340B covered entity 17will place an order for a 340B drug to replenish the same prior 18pharmacy dispense. The policy shall also include a process to 19reimburse a manufacturer for any duplicate 340B discount the 20covered entity receives. The policy shall be filed annually 21with the General Assembly. 22    Section 40. Enforcement.23    (a) The Attorney General is authorized to enforce this Act   10400HB2371sam002- 8 -LRB104 06098 BAB 26897 a1under its general authority under the Attorney General Act.2    (b) Upon finding a violation of Section 15 of this Act, a 3court may order:4        (1) temporary, preliminary, or permanent injunctive 5    relief for any act, policy, or practice that violates this 6    Act;7        (2) money damages to be paid to the 340B covered 8    entity as a result of the violation of this Act;9        (3) the assessment of a civil penalty of up to $1,000 10    for each violation of Section 15; or11        (4) any other relief. 12    Section 45. Preemption. 13    (a) Nothing in this Act shall be construed or applied to be 14less restrictive than federal law for a person regulated by 15this Act.16    (b) Nothing in this Act shall be construed or applied in a 17manner that would conflict with:18        (1) applicable federal law; or19        (2) other laws of this State if the State law is 20    compatible with applicable federal law.21    (c) Limited distribution of a drug required under 21 22U.S.C. 355-1 may not to be construed as a violation of this 23Act. 24    Section 97. Severability. If any provision of this Act or   10400HB2371sam002- 9 -LRB104 06098 BAB 26897 a1its application to any person or circumstance is held invalid, 2the invalidity of that provision or application does not 3affect other provisions or applications of this Act that can 4be given effect without the invalid provision or application. 5Each paragraph defining "340B contract pharmacy" in Section 10 6is severable. 7    Section 99. Effective date. This Act takes effect upon 8becoming law.".